ProMIS Neurosciences, Inc.
PMN.TO
Toronto Stock Exchange6.00
CAD
-0.24
- -
ProMIS Neurosciences, Inc.
PMN.TO
(Toronto Stock Exchange)
Recent
price
6.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ProMIS Neurosciences, Inc. ProMIS Neurosciences, Inc. (Nasdaq: PMN) is a clinical-stage biotechnology company that discovers and develops antibody therapeutics and therapeutic vaccines selectively targeting toxic misfolded proteins in neurodegenerative diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA); the company employs its proprietary ProMIS and Collective Coordinates computational discovery platforms, along with the EpiSelect target discovery engine, to predict disease-specific epitopes on misfolded proteins such as amyloid-beta, TDP-43, and alpha-synuclein. Its lead product candidates include PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers for AD currently advancing in Phase 1b clinical trials with recent DSMB approval for final dose escalation in September 2025; PMN267, a monoclonal antibody for TDP-43 misfolding in ALS; PMN442, a monoclonal antibody targeting toxic alpha-synuclein oligomers for MSA; and vaccines such as PMN440 for alpha-synucleinopathies and PMN311 for amyloid-beta in AD, with additional programs addressing frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. Founded in 2004 and headquartered at 1920 Yonge Street, Suite 200 in Toronto, Ontario, Canada, with additional offices in Cambridge, Massachusetts, the company operates primarily in Canada and the United States, targeting patients with rare and prevalent neurodegenerative disorders driven by protein misfolding. Recent developments include a $2.4 million private placement financing in July 2025 to support PMN310 clinical development, yielding total proceeds of approximately $9.2 million including warrants; a one-for-twenty-five reverse stock split announced on November 24, 2025, effective November 28; board appointment of Slanix Paul Alex, Pharm.D., from Ally Bridge Group in October 2025; a $0.8 million registered direct offering in July 2025; and presentation of its protein-misfolding platform and PRECISE-AD trial design at the 2025 Alzheimer’s Association International Conference.